June 4, 2020 / 11:21 AM / a month ago

BRIEF-Can-Fite Concludes Meeting With EMA Regarding Phase III Trial For Namodenoson

June 4 (Reuters) - Can Fite Biopharma Ltd:

* CAN-FITE CONCLUDES SUCCESSFUL MEETING WITH EUROPEAN MEDICINES AGENCY (EMA) REGARDING PHASE III TRIAL AND REGISTRATION PLAN FOR NAMODENOSON IN THE TREATMENT OF LIVER CANCER

* CAN FITE - FOLLOWING MEETINGS WITH U.S. FDA & EMA, CO TO SUBMIT PROTOCOL,CONDUCT 1 PIVOTAL TRIAL FOR REGISTRATION IN BOTH MARKETS FOR NAMODENOSON Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below